Following people in Costa Rica with atopic dermatitis who take dupilumab or JAK inhibitors
Follows people with atopic dermatitis treated with dupilumab or JAK inhibitors in Costa Rica.
Key facts
- Who runs it
- Caja Costarricense de Seguro Social
- Where
- San José, Costa RicaSee the site
- Trial code
- Registry title
- Atopic Dermatitis Treated With Dupilumab and JAK Inhibitors in Costa Rica
- Status
- Not yet recruiting
- People taking part
- 50 people, planned
- Started
- May 2026
- Expected to end
- May 2031
- Type of study
- Observational
- Treatments tested
- Abrocitinib
- Upadacitinib
- Baricitinib
- Dupilumab
- Record updated
- 8 April 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The registry is looking for people in Costa Rica with moderate-to-severe atopic dermatitis who already get systemic or advanced treatment as part of their usual care.
- Sex
- Everyone can join.
- Disease stage
- Moderate-to-severe atopic dermatitis that needs systemic or advanced therapy.
- Earlier treatment
- Must be getting systemic immunosuppressive, biologic, or other advanced treatment as part of routine care.
Main reasons for not taking part
- Not enough clinical data to assess severity or treatment
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- Clinical diagnosis of atopic dermatitis according to accepted diagnostic criteria
- Moderate-to-severe disease requiring systemic or advanced therapy
- Receiving systemic immunosuppressive, biologic, or other advanced treatment as part of routine care
- Evaluated in participating dermatology centers in Costa Rica
- Available clinical records with baseline and follow-up information
Who cannot take part
- Lack of sufficient clinical data for severity or treatment assessment
Where in Costa Rica
- Caja Costarricense del Seguro SocialSan José, Costa RicaContact: Daniel E Barquero-Orias, DermatologistNot yet recruiting
About the trial
What the trial wants to find out
The goal of this observational registry is to characterize the clinical features, severity, treatments, and outcomes of patients with atopic dermatitis in Costa Rica receiving systemic and advanced therapies in routine clinical practice. The main questions it aims to answer are:
Read full original descriptionShow less
What are the demographic and clinical characteristics of patients with moderate-to-severe atopic dermatitis treated in specialized dermatology centers in Costa Rica?
What treatments are used in real-world practice and how do they impact disease severity and patient-reported outcomes over time?
Participants with atopic dermatitis receiving systemic or advanced therapies as part of their usual medical care will be followed longitudinally, with collection of clinical severity scores, treatment patterns, and outcomes during routine visits.
Treatments tested
- Abrocitinib
- Upadacitinib
- Baricitinib
- Dupilumab
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- National Registry of Patients With Atopic Dermatitis Under Treatment With Dupilumab and JAK Inhibitors Within the Costa Rican Social Security System
- Plain-language title
- Following people in Costa Rica with atopic dermatitis who take dupilumab or JAK inhibitorsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 13 November 2026.
- Record updated
- 8 April 2026